Anupriya Dhonchak News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Anupriya dhonchak. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Anupriya Dhonchak Today - Breaking & Trending Today

Morning Brief Podcast: Copy vs Copyright: Whose content is it anyway?

Humans of Bombay opens the floodgates to the copyright conversation for creators while controversies around AP Dhillon’s Dil Nu to Made In Heaven script take centre stage. From voice identity to idea protection to direct reshares, creators are facing an uphill battle where copying is moving faster than copyright laws. When remixes and reshares become ripoffs - What options do creators have to protect their work? And is it even feasible? What role do platforms play that encourage engagement at ‘any cost’? TMB Host Apoorva Mittal opens the pandora’s box of plagiarism with content creator Varun Duggirala, Anupriya Dhonchak, MPhil in Law, Oxford and Shephali Bhatt, ET s internet culture reporter. Listen In! ....

Shephali Bhatt , Varun Duggirala , Apoorva Mittal , Anupriya Dhonchak , Made In Heaven , Read Moreny , Made In Heaven Script , Copyright Issue , Copyright Conversation , Copy Vs Copyright ,

Covid-19 vaccine: Who owns the IP rights to Bharat Biotech's publicly funded Covaxin?


A woman being vaccinated in Ahmedabad.
|
Reuters/Amit Dave
On Saturday, the pharmaceutical company Bharat Biotech officially announced the sale prices for its Covid-19 vaccine, Covaxin. State governments will have to pay Rs 600 per dose while private hospitals will have to pay Rs 1,200 per dose. These prices, fixed far above the corresponding rates announced by the Serum Institute of India for its vaccine, Covishield, has surprised observers for many reasons.
The Serum Institute could cite royalty payments to the Swedish-Britsh firm AstraZeneca from which it has licensed its vaccine as a potential reason for higher prices. But Bharat Biotech does not have to pay any royalty for Covaxin. Covaxin is, in large measure, a product of publicly funded research in India. ....

United States , United Kingdom , New Delhi , Anupriya Dhonchak , Anik Bhaduri , Balaram Bhargava , National Institute Of Virology , Indian Council For Medical Research , European Commission , Ministry Of Health , Serum Institute , Serum Institute Of India , Oxford University , Haffkine Institute , Bharat Biotech , National Institute , Indian Council , Bharati Biotech , General Balaram Bhargava , Independence Day , General Financial Rules , Family Welfare , Clinical Trial , United Kingdom Variant , Travel Medicine , Efficacy Study ,